The Journal of Allergy and Clinical Immunology
Volume 119, Issue 6 , Pages 1291-1300 , June 2007

Eosinophilic disorders

  • Dagmar Simon, MD

      Affiliations

    • From the Departments of Dermatology, Inselspital
  • ,
  • Hans-Uwe Simon, MD, PhD

      Affiliations

    • Pharmacology, University of Bern
    • Corresponding Author InformationReprint requests: Hans-Uwe Simon, MD, PhD, Department of Pharmacology, University of Bern, Friedbühlstrasse 49, CH-3010 Bern, Switzerland.

Received 15 January 2007 ,Revised 12 February 2007 ,Accepted 13 February 2007.

  • Image Result

    Classification of eosinophilic disorders. Eosinophilia is either mediated by cytokines (in particular IL-5) or a consequence of mutations in hematopoietic stem cells leading to predominant eosinophil

    Classification of eosinophilic disorders. Eosinophilia is either mediated by cytokines (in particular IL-5) or a consequence of mutations in hematopoietic stem cells leading to predominant eosinophil differentiation. Interestingly, even patients with idiopathic (hyper)eosinophilia can be integrated in this simple scheme as soon as information regarding cytokine expression and/or the imatinib response is available.

  • Image Result
    A proposed algorithm to diagnose eosinophilic disorders. In the first step (step 1), patients should be screened for common triggers of eosinophilia. If no likely cause of eosinophilia is identified,

    A proposed algorithm to diagnose eosinophilic disorders. In the first step (step 1), patients should be screened for common triggers of eosinophilia. If no likely cause of eosinophilia is identified, a potential involvement of eosinophil hematopoietins should directly be investigated (step 2). Unfortunately, if no cytokine levels can be detected in serum, an extrinsic eosinophilic disorder cannot be excluded, and no routine assays are currently available regarding in vitro cytokine production by T cells (∗). If there is evidence for a cytokine-driven process, specialized laboratories (immunology-oriented) should be contacted to identify the cytokine-producing cell, and a tumor should be excluded (step 3). Similarly, if the cytokine analysis is negative, further diagnostic procedures should also be performed by specialized laboratories (hematology-oriented) to answer the question whether a stem cell disorder might be the underlining cause of eosinophilia (step 3).

 (Supported by an unrestricted educational grant from Genentech, Inc. and Novartis Pharmaceuticals Corporation)Series editors: Donald Y. M. Leung, MD, PhD, and Dennis K. Ledford, MDWork in the laboratory of Dr Hans-Uwe Simon is supported by grants from the Swiss National Science Foundation (grant #310000-107526), the Stanley Thomas Johnson Foundation, Bern, and the OPO-Foundation, Zurich.Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.

PII: S0091-6749(07)00377-6

doi: 10.1016/j.jaci.2007.02.010

The Journal of Allergy and Clinical Immunology
Volume 119, Issue 6 , Pages 1291-1300 , June 2007